Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

About Ligand Pharmaceuticals

Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LGND
  • CUSIP: 53220K50
Key Metrics:
  • Previous Close: $103.41
  • 50 Day Moving Average: $122.07
  • 200 Day Moving Average: $114.14
  • Trailing P/E Ratio: 9.75
  • Foreward P/E Ratio: 19.29
  • P/E Growth: 0.65
  • Market Cap: $2.16B
  • Outstanding Shares: 20,854,000
  • Beta: 1.09
Additional Links:
Companies Related to Ligand Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 1 Sell Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $139.00 (34.42% upside)

Analysts' Ratings History for Ligand Pharmaceuticals (NASDAQ:LGND)
DateFirmActionRatingPrice TargetDetails
8/14/2016Roth CapitalReiterated RatingBuy$149.00View Rating Details
8/5/2016Deutsche Bank AGDowngradeHold -> Sell$104.00 -> $110.00View Rating Details
4/13/2016StephensInitiated CoverageOverweight$150.00View Rating Details
3/11/2016SidotiInitiated CoverageBuy$140.00View Rating Details
3/3/2016HC WainwrightInitiated CoverageBuy$146.00View Rating Details
6/19/2015Cantor FitzgeraldBoost Price TargetHold$86.00 -> $93.00View Rating Details
5/23/2015Craig HallumReiterated RatingBuy$90.00 -> $105.00View Rating Details
3/3/2015CRT CapitalInitiated CoverageBuy$102.00View Rating Details
10/8/2014ING GroupReiterated RatingBuyView Rating Details
(Data available from 8/30/2014 forward)


Earnings History for Ligand Pharmaceuticals (NASDAQ:LGND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.65$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.81$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.27$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.60$0.60$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.31$0.36$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ligand Pharmaceuticals (NASDAQ:LGND)
Current Year EPS Consensus Estimate: $3.05 EPS
Next Year EPS Consensus Estimate: $5.36 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.44$0.46$0.45
Q2 20161$0.54$0.54$0.54
Q3 20162$0.62$0.63$0.63
Q4 20162$1.08$1.16$1.12
(Data provided by Zacks Investment Research)


Dividend History for Ligand Pharmaceuticals (NASDAQ:LGND)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Ligand Pharmaceuticals (NASDAQ:LGND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.00View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.00View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Ligand Pharmaceuticals (NASDAQ:LGND)
DateHeadline logoStocks in Focus: Ligand Pharmaceuticals Incorporated (NASDAQ ... - KC Register (NASDAQ:LGND) - August 26 at 5:45 PM
News IconLigand Pharmaceuticals Inc. (NASDAQ:LGND) Analyst Opinion - The Independent Republic (NASDAQ:LGND) - August 26 at 5:45 PM logoLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements an (NASDAQ:LGND) - August 26 at 8:57 AM logoRough Month: A Closer Look At Ligand's Fall From All-Time Highs (NASDAQ:LGND) - August 24 at 5:48 PM logoETF’s with exposure to Ligand Pharmaceuticals, Inc. : August 24, 2016 (NASDAQ:LGND) - August 24 at 5:48 PM logoThese 3 Stocks Are Up Over 700% in the Last 5 Years (NASDAQ:LGND) - August 23 at 6:08 PM logoLigand Pharmaceuticals (LGND) Shares Cross Below 200 DMA - Nasdaq (NASDAQ:LGND) - August 19 at 5:54 PM logoLigand Pharmaceuticals (LGND) Is in Oversold Territory: What's Next? (NASDAQ:LGND) - August 19 at 5:54 PM logoLigand Down 20% Since August 1; What's The Street Thinking? (NASDAQ:LGND) - August 17 at 6:08 PM logoLigand Pharmaceuticals (LGND) Shares Cross Below 200 DMA (NASDAQ:LGND) - August 17 at 6:08 PM logoVKTX: Data From Phase 2 Studies of VK2809 for Hypercholersterolemia and VK5211 for Hip Fracture to be Reported in 2Q17 (NASDAQ:LGND) - August 16 at 6:03 PM logoLIGAND PHARMACEUTICALS INC Financials (NASDAQ:LGND) - August 12 at 6:02 PM logoLigand Pharmaceuticals Still Offers Double-Digits Upside, Vetr Crowd Says (NASDAQ:LGND) - August 11 at 6:12 PM logoETF’s with exposure to Ligand Pharmaceuticals, Inc. : August 9, 2016 (NASDAQ:LGND) - August 9 at 6:08 PM logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : August 9, 2016 (NASDAQ:LGND) - August 9 at 8:59 AM logoLigand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NASDAQ:LGND) - August 8 at 6:09 PM logoDeutsche Downgrades Ligand As Risk/Reward Becomes Challenging (NASDAQ:LGND) - August 5 at 6:03 PM logoEdited Transcript of LGND earnings conference call or presentation 4-Aug-16 1:00pm GMT (NASDAQ:LGND) - August 5 at 6:03 PM logoLigand Pharma downgraded by Deutsche Bank (NASDAQ:LGND) - August 5 at 6:03 PM logoLigand reports 2Q loss (NASDAQ:LGND) - August 4 at 6:17 PM logoLigand (LGND) Beats Q2 Earnings, Revenues Up Y/Y (NASDAQ:LGND) - August 4 at 9:01 AM logoLigand Pharmaceuticals Inc Earnings Fall 72% In Q2 (NASDAQ:LGND) - August 4 at 9:01 AM logoQ2 2016 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open (NASDAQ:LGND) - August 4 at 9:01 AM logoLigand Reports Second Quarter 2016 Financial Results (NASDAQ:LGND) - August 4 at 9:01 AM logoLigand (LGND) Q2 Earnings: What's in Store for the Stock ... - Nasdaq (NASDAQ:LGND) - August 2 at 10:46 AM logoLigand (LGND) Q2 Earnings: What's in Store for the Stock? (NASDAQ:LGND) - August 2 at 10:46 AM logoLigand Pharmaceuticals : Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals (NASDAQ:LGND) - July 29 at 6:05 PM logoLigand Pharma (LGND) Enters LTP Tech Licensing Agreement (NASDAQ:LGND) - July 29 at 6:05 PM logoLigand Pharma (LGND) Enters LTP Tech Licensing Agreement - (NASDAQ:LGND) - July 29 at 8:55 AM logoLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events (NASDAQ:LGND) - July 29 at 8:50 AM logoLigand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals (NASDAQ:LGND) - July 29 at 8:30 AM logoLigand Pharmaceuticals Reaches Analyst Target Price - Nasdaq (NASDAQ:LGND) - July 22 at 8:54 AM
News IconLigand Pharmaceuticals Inc. Stock Is Rising Now - Consumer Eagle (NASDAQ:LGND) - July 22 at 8:54 AM logoLigand Pharmaceuticals Reaches Analyst Target Price (NASDAQ:LGND) - July 21 at 12:05 PM logoLigand Pharmaceuticals Incorporated (LGND) Jumps 5.52% on July 20 - (NASDAQ:LGND) - July 20 at 10:28 PM
News IconLigand Pharmaceuticals Inc. Hit 52-Week High - Press Telegraph (NASDAQ:LGND) - July 20 at 10:28 PM
News IconWhat Will Happen to Ligand Pharmaceuticals Inc. Next? The Stock Formed a Several Months Double Top Pattern - Consumer Eagle (NASDAQ:LGND) - July 18 at 6:07 PM logoHow Much Potential Does Promacta Hold? (NASDAQ:LGND) - July 18 at 11:07 AM logoLigand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst (NASDAQ:LGND) - July 18 at 9:08 AM logoLigand Pharmaceuticals Inc (NASDAQ:LGND): Continue to Grow - Street Report (NASDAQ:LGND) - July 15 at 10:03 AM
News IconTurner Investments LP Increased Ligand Pharmaceuticals INC (NASDAQ:LGND) by $4.39 Million as Shares Rose - Consumer Eagle (NASDAQ:LGND) - July 14 at 9:32 AM logoLigand to Report Second Quarter Results on August 4th (NASDAQ:LGND) - July 14 at 9:00 AM logoHere's Why SAGE Therapeutics Inc. Is Surging Today - Motley Fool (NASDAQ:LGND) - July 12 at 6:12 PM logoSage Therapeutics' Post-Partum Depression Drug Scores; Stock Up (NASDAQ:LGND) - July 12 at 4:07 PM logoHere's Why SAGE Therapeutics Inc. Is Surging Today (NASDAQ:LGND) - July 12 at 12:31 PM
News IconLigand Pharmaceuticals (NASDAQ:LGND) Sellers Covered 0.86% of Their Shorts - Press Telegraph (NASDAQ:LGND) - July 11 at 10:38 AM logoLigand Pharma (LGND) Enters OmniAb Licensing Agreement with Gilead (GILD) (NASDAQ:LGND) - July 10 at 5:28 PM logoLigand Enters into OmniAb® Platform License Agreement with Gilead Sciences (NASDAQ:LGND) - July 10 at 5:28 PM logoLigand Pharma (LGND) Enters OmniAb Licensing Agreement with Gilead (GILD) - (NASDAQ:LGND) - July 8 at 6:02 PM logoLigand Reaches OmniAb Platform License Agreement with Gilead (NASDAQ:LGND) - July 8 at 11:54 AM


Ligand Pharmaceuticals (NASDAQ:LGND) Chart for Tuesday, August, 30, 2016

Last Updated on 8/30/2016 by Staff